KALA BIO (NASDAQ:KALA) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of KALA BIO (NASDAQ:KALA) in a research report sent to investors on Monday, Marketbeat.com reports.

Several other analysts have also recently issued reports on the stock. Mizuho initiated coverage on shares of KALA BIO in a report on Monday, September 8th. They issued an “outperform” rating and a $30.00 price target on the stock. LADENBURG THALM/SH SH lowered shares of KALA BIO from a “buy” rating to a “neutral” rating in a research note on Monday. Wall Street Zen cut shares of KALA BIO from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Oppenheimer boosted their price objective on KALA BIO from $15.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 11th. Finally, Lifesci Capital upgraded KALA BIO to a “strong-buy” rating in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.50.

KALA BIO Stock Down 89.2%

Shares of NASDAQ:KALA opened at $2.05 on Monday. The stock has a 50-day simple moving average of $11.31 and a 200-day simple moving average of $6.88. The stock has a market capitalization of $14.39 million, a P/E ratio of -0.30 and a beta of -1.82. KALA BIO has a 1 year low of $1.10 and a 1 year high of $20.60. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.10 and a current ratio of 2.10.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.82) by $0.11. Equities analysts forecast that KALA BIO will post -10.84 earnings per share for the current year.

Institutional Trading of KALA BIO

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AIGH Capital Management LLC lifted its position in shares of KALA BIO by 52.8% during the 2nd quarter. AIGH Capital Management LLC now owns 300,000 shares of the company’s stock valued at $1,428,000 after acquiring an additional 103,650 shares during the last quarter. ADAR1 Capital Management LLC raised its position in shares of KALA BIO by 35.7% during the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock worth $1,713,000 after purchasing an additional 78,582 shares during the period. Woodline Partners LP purchased a new stake in shares of KALA BIO during the first quarter valued at $1,483,000. Geode Capital Management LLC lifted its holdings in shares of KALA BIO by 2.8% during the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after purchasing an additional 1,534 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new position in shares of KALA BIO in the 1st quarter valued at $243,000. 24.61% of the stock is owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.